000301479 001__ 301479
000301479 005__ 20250525020723.0
000301479 0247_ $$2doi$$a10.1093/noajnl/vdae226
000301479 0247_ $$2pmid$$apmid:40376681
000301479 0247_ $$2pmc$$apmc:PMC12080555
000301479 0247_ $$2altmetric$$aaltmetric:173086836
000301479 037__ $$aDKFZ-2025-01021
000301479 041__ $$aEnglish
000301479 082__ $$a610
000301479 1001_ $$aMühlenbruch, Lena$$b0
000301479 245__ $$aThe immunopeptidomic landscape of ependymomas provides actionable antigens for T-cell-based immunotherapy.
000301479 260__ $$aOxford$$bOxford University Press$$c2025
000301479 3367_ $$2DRIVER$$aarticle
000301479 3367_ $$2DataCite$$aOutput Types/Journal article
000301479 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747730645_3491
000301479 3367_ $$2BibTeX$$aARTICLE
000301479 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301479 3367_ $$00$$2EndNote$$aJournal Article
000301479 520__ $$aEpendymoma are primary tumors of the nervous system. Due to their growth pattern, many ependymomas can be managed with neurosurgical resection alone. A substantial proportion of these tumors recurs or displays infiltrative growth patterns. Further established therapeutic options include radiation therapy. Systemic treatment options include platinum-based therapeutic regimes or a combination of lapatinib and temozolomide. Peptide-based immunotherapy represents a promising therapeutic strategy relying on the induction of tumor-specific T cells targeting human leukocyte antigens (HLA)-presented peptides. Our work aimed to analyze the landscape of naturally presented HLA class I and II ligands of primary ependymomas (EPN) to delineate EPN-associated antigens.We investigated 22 EPN tissue samples using a comparative mass spectrometry-based immunopeptidomic approach. Additionally, EPN-specific antigens were functionally characterized in T-cell-based immunogenicity assays.We discovered a subset of EPN-exclusive peptides including HLA-A*02 and HLA-A*25/HLA-A*26-restricted HLA ligands and identified a small panel of cancer/testis antigens (CTAs)-derived HLA ligands. Furthermore, we outlined immunopeptidomic alterations in different ependymoma subgroups and progressive ependymoma. Subsequently, we performed functional characterization of the previously identified HLA-A*02:01 restricted peptide FLDS to demonstrate immunogenicity in vitro.The immunopeptidome landscape of EPNs provides actionable targets that could further be explored as a T cell-based immunotherapeutic strategy in this tumor entity.
000301479 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000301479 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301479 650_7 $$2Other$$aHLA ligands
000301479 650_7 $$2Other$$acancer vaccination
000301479 650_7 $$2Other$$aimmunotherapy
000301479 650_7 $$2Other$$amass spectrometry
000301479 650_7 $$2Other$$apeptide vaccine
000301479 7001_ $$aRieger, David$$b1
000301479 7001_ $$aBecker, Hannes$$b2
000301479 7001_ $$aSantos Leite, Ana Maia$$b3
000301479 7001_ $$aMäurer, Irina$$b4
000301479 7001_ $$00000-0002-9168-6209$$aSchittenhelm, Jens$$b5
000301479 7001_ $$aDubbelaar, Marissa$$b6
000301479 7001_ $$aBichmann, Leon$$b7
000301479 7001_ $$00000-0003-1739-4598$$aKohlbacher, Oliver$$b8
000301479 7001_ $$0P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc$$aRammensee, Hans-Georg$$b9
000301479 7001_ $$0P:(DE-HGF)0$$aGouttefangeas, Cécile$$b10
000301479 7001_ $$0P:(DE-HGF)0$$aTatagiba, Marcos$$b11
000301479 7001_ $$0P:(DE-He78)aa8b428f7b1df6694113a5a7d3c4832a$$aWalz, Juliane$$b12$$udkfz
000301479 7001_ $$0P:(DE-He78)d53ff17be4b468909d803eccd92df3d6$$aTabatabai, Ghazaleh$$b13$$udkfz
000301479 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdae226$$gVol. 7, no. 1, p. vdae226$$n1$$pvdae226$$tNeuro-oncology advances$$v7$$x2632-2498$$y2025
000301479 909CO $$ooai:inrepo02.dkfz.de:301479$$pVDB
000301479 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-9168-6209$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000301479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)58a4f09f3edfdce451d520a5be7979fc$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000301479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000301479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000301479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)aa8b428f7b1df6694113a5a7d3c4832a$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000301479 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d53ff17be4b468909d803eccd92df3d6$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000301479 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000301479 9141_ $$y2025
000301479 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOL ADV : 2022$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-03T10:37:56Z
000301479 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-03T10:37:56Z
000301479 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-03T10:37:56Z
000301479 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-18
000301479 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-18
000301479 9201_ $$0I:(DE-He78)TU01-20160331$$kTU01$$lDKTK Koordinierungsstelle Tübingen$$x0
000301479 980__ $$ajournal
000301479 980__ $$aVDB
000301479 980__ $$aI:(DE-He78)TU01-20160331
000301479 980__ $$aUNRESTRICTED